Derek Yoon
Director/Board Member at ARCELLX, INC.
Profile
Derek Yoon is currently the President & CEO of Solasta Ventures, Inc. and an Independent Director at Arcellx, Inc. He is also a Director at Carbon Biosciences, Inc. and currently holds positions as an Analyst at Aju IB Investment Co., Ltd.
(Private Equity) and a Partner at Aju IB Investment US.
In the past, he has served as an Independent Director at Clearside Biomedical, Inc. and Trefoil Therapeutics, Inc. He has also worked as a Portfolio Manager-Healthcare Banking at Citizens Bank, NA (Providence, Rhode Island) and an Investment Manager at Berwind LLC (Massachusetts).
Mr. Yoon holds a graduate degree and an MBA from Babson College, a graduate degree from Boston College, and an undergraduate degree from Yonsei University.
Derek Yoon active positions
| Companies | Position | Start |
|---|---|---|
| ARCELLX, INC. | Director/Board Member | 2020-03-31 |
| Aju IB Investment US | Corporate Officer/Principal | - |
Solasta Ventures, Inc.
 Solasta Ventures, Inc. Investment ManagersFinance Solasta Ventures Inc (Solasta Ventures) is a venture capital division of AJU IB Investment Co Ltd (South Korea) founded in 2019. The firm is headquartered in Boston, Massachusetts. | Chief Executive Officer | 2019-06-30 |
Aju IB Investment Co., Ltd. (Private Equity)
 Aju IB Investment Co., Ltd. (Private Equity) Investment ManagersFinance Aju IB Investment Co., Ltd. (Aju IB) is the venture capital subsidiary of AJU Capital Co., Ltd founded in 1974 by Korea Technology Development Corp. The firm is headquartered in Seoul, Korea. | Private Equity Analyst | - |
Carbon Biosciences, Inc.
 Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Director/Board Member | - |
Former positions of Derek Yoon
| Companies | Position | End |
|---|---|---|
| CLEARSIDE BIOMEDICAL, INC. | Director/Board Member | 2017-08-07 |
Trefoil Therapeutics, Inc.
 Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA. | Director/Board Member | 2017-07-31 |
Citizens Bank, NA (Providence, Rhode Island)
 Citizens Bank, NA (Providence, Rhode Island) Major BanksFinance Citizens Bank NA provides commercial banking services. It offers credit cards, borrowing services, student lending solutions, retirement plans, and wealth management and investment services. The company is headquartered in Providence, RI. | Corporate Officer/Principal | 2013-11-30 |
Berwind LLC (Massachusetts)
 Berwind LLC (Massachusetts) Investment ManagersFinance Berwind LLC (Berwind) is a venture capital/private equity firm founded in 2000. The firm is headquartered in Harvard, Massachusetts. | Chief Investment Officer | 2011-03-31 |
Training of Derek Yoon
| Babson College | Graduate Degree |
| Boston College | Graduate Degree |
| Yonsei University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| CLEARSIDE BIOMEDICAL, INC. | Health Technology |
| ARCELLX, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Aju IB Investment Co., Ltd. (Private Equity)
Aju IB Investment Co., Ltd. (Private Equity) Investment ManagersFinance Aju IB Investment Co., Ltd. (Aju IB) is the venture capital subsidiary of AJU Capital Co., Ltd founded in 1974 by Korea Technology Development Corp. The firm is headquartered in Seoul, Korea. | Finance |
Citizens Bank, NA (Providence, Rhode Island)
Citizens Bank, NA (Providence, Rhode Island) Major BanksFinance Citizens Bank NA provides commercial banking services. It offers credit cards, borrowing services, student lending solutions, retirement plans, and wealth management and investment services. The company is headquartered in Providence, RI. | Finance |
Berwind LLC (Massachusetts)
Berwind LLC (Massachusetts) Investment ManagersFinance Berwind LLC (Berwind) is a venture capital/private equity firm founded in 2000. The firm is headquartered in Harvard, Massachusetts. | Finance |
| Aju IB Investment US | |
Trefoil Therapeutics, Inc.
Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA. | Health Technology |
Solasta Ventures, Inc.
Solasta Ventures, Inc. Investment ManagersFinance Solasta Ventures Inc (Solasta Ventures) is a venture capital division of AJU IB Investment Co Ltd (South Korea) founded in 2019. The firm is headquartered in Boston, Massachusetts. | Finance |
Carbon Biosciences, Inc.
Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Health Services |
- Stock Market
- Insiders
- Derek Yoon
